Vericel Corporation (VCEL)

Market Cap	2.48B
Revenue (ttm)	237.22M
Net Income (ttm)	10.36M
Shares Out	49.97M
EPS (ttm)	0.20
PE Ratio	247.80
Forward PE	164.11
Dividend	n/a
Ex-Dividend Date	n/a

Volume	450,523
Open	48.43
Previous Close	48.76
Day's Range	47.08 - 50.31
52-Week Range	39.12 - 63.00
Beta	1.79
Analysts	Strong Buy
Price Target	63.00 (+27.12%)
Earnings Date	Feb 27, 2025

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 1997
• Employees: 357
• Stock Exchange: NASDAQ
• Ticker Symbol: VCEL
• Website: https://vcel.com

Analyst Forecast

According to 8 analysts, the average rating for VCEL stock is "Strong Buy." The 12-month stock price forecast is $63.0, which is an increase of 27.12% from the latest price.

Price Target

$63.0

(27.12% upside)

Analyst Consensus: Strong Buy